Premium
Eugenia punicifolia (Kunth) DC. as an Adjuvant Treatment for Type‐2 Diabetes Mellitus: A non‐Controlled, Pilot Study
Author(s) -
Sales Débora Simone,
Carmona Fabio,
Azevedo Bruna Cestari,
TalebContini Silvia Helena,
Bartolomeu Ana Carolina Duó,
Honorato Fernando B.,
Martinez Edson Z.,
Pereira Ana Maria Soares
Publication year - 2014
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5206
Subject(s) - medicine , postprandial , adjuvant , gallic acid , traditional medicine , type 2 diabetes mellitus , gastroenterology , diabetes mellitus , pharmacology , insulin , endocrinology , biochemistry , antioxidant , chemistry
Type‐2 diabetes mellitus (DM) is a highly prevalent disease with significant morbidity and mortality around the world. However, there is no universally effective treatment, because response to different treatment regimens can vary widely among patients. In this study, we aimed to investigate whether the use of the powdered dried leaves of Eugenia punicifolia (Kunth) DC. (Myrtaceae) is effective as an adjuvant to the treatment of patients with type‐2 DM. Fifteen patients were enrolled in a pilot, non‐controlled study, and received E . punicifolia for 3 months. After treatment, we observed a significant decrease in glycosylated hemoglobin, basal insulin, thyroid‐stimulating hormone, C‐reactive protein, and both systolic and diastolic blood pressure. There were no changes in fasting and postprandial glycemia. The compounds myricetin‐3‐ O ‐rhamnoside, quercetin‐3‐ O ‐galactoside, quercetin‐3‐ O ‐xyloside, quercetin‐3‐ O ‐rhamnoside, kaempferol‐3‐ O ‐rhamnoside, phytol, gallic acid, and trans‐caryophyllene present in the powdered dried leaves of E . punicifolia may be responsible for the therapeutic effect. In conclusion, the powdered leaves of E . punicifolia are promising as an adjuvant in the treatment of type‐2 DM and deserve further investigation. Copyright © 2014 John Wiley & Sons, Ltd.